Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.72 |
| ▸ | DRD4 | P21917 | 5/20 | 0.72 |
| ▸ | DRD3 | P35462 | 5/20 | 0.72 |
| ▸ | DRD1 | P21728 | 3/20 | 0.72 |
| ▸ | DRD5 | P21918 | 3/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | PRCP | P42785 | 1/20 | 0.58 |
| ▸ | EBP | Q15125 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16410879 | 0.87 | DRD2 (0.54) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL1546230 | 0.84 | DRD3 (1.00) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL1546231 | 0.84 | DRD3 (1.00) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL12841897 | 0.82 | DRD2 (0.70) | DRD2SIGMAR1 | |
| SCHEMBL1546881 | 0.81 | DRD4 (0.72) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL1638067 | 0.81 | DRD3 (0.72) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL1547055 | 0.81 | DRD4 (0.72) | DRD2DRD4DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL10352095 | 0.81 | DRD2 (0.70) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL20611963 | 0.80 | LSS (0.50) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL18744076 | 0.80 | DRD2 (0.47) | DRD2DRD4DRD3DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624211-B2 | Anti-cancer compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160145250-A1 | ANTI-CANCER COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145250-A1 | ANTI-CANCER COMPOUNDS | SKP2, TP53, TEAD2 | DRD2 3791/4885DRD4 3147/4885DRD3 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.